Issuu on Google+


Preparing for threats and opportunities impacting products, platforms or markets

Biosimilars Market Entry Market insight Strategy development

Managing Disruptions Personalized Healthcare Competitor Analysis

Maximizing opportunities and mitigating risks created by new market dynamics

Product launch support and guidance

Future Disruptors Market Monitoring Interpreting and Prioritizing

BIOSIMILARS Datamonitor Consulting’s Biosimilars Practice provides deep insight into the biosimilars landscape. We support you in understanding and quantifying the potential challenges and opportunities within the market. Aligned with many of Datamonitor Consulting’s other areas of expertise, our consultants are able to advise on biologics LCM strategy, provide insights into biosimilar opportunity assessments (including forecasting, licensing and partnership opportunities) and support you in keeping up to date with the ever-changing biosimilars landscape.

The impact of 'market disruptors' can be felt along the whole product lifecycle, from early stage R&D and innovation through to mature product LCM strategies. Datamonitor Consulting analyzes market disruptors to help you understand the impact, your options, and potential for commercial gain. This is developed into an action plan to mitigate risk and/or maximize opportunity. To ensure that you are ahead of the game, our surveillance trackers and defence/opportunity plans help you prepare for developments in the marketplace. We inform your decision making to help you to commercially position your brand and product portfolio in alignment with market trends. We support your thorough understanding of all facts, possibilities and options; we go beyond information sourcing to interpret the likely threats and opportunities you're facing.

PERSONALIZED HEALTHCARE Datamonitor Consulting provides detailed assessments of the opportunities and threats that personalized healthcare provides, considering key stakeholders including payers, regulators and physicians. Through in-depth insight and analysis we look at how the market is changing and how it will impact your product/portfolio. Our consultants inform your decision making processes through a combination of total market analysis and assessment of implications for your brand. This incorporates a gap analysis and assessment of market forces and their implications.

Our consultants operate globally; our head offices are located in: UK 119 Farringdon Road, London EC1R 3DA | +44 (0)20 7675 7000 US 52 Vanderbilt Avenue, 7th Floor, New York, NY 10017 | +1 (212) 686 7400 Japan 7th Kotakudo GINZA Building, 5-14-5, Ginza, Chuo, Tokyo 104-0061 | +81 (0)3 5148 7910

Results in Practice: How We’ve Helped Others

OUR EXPERTISE Our specialists’ deep-level expertise in biosimilars and personalized healthcare is gained from past positions within biopharmaceutical, biotech, clinical research and management consulting organizations. We provide consultants with expertise in: • Finding, understanding and quantifying risks and opportunities • Supporting the development of actionable lifecycle management (LCM) strategies for biologic assets • Thought leadership with expert understanding of market dynamics • Interpreting what market changes mean to you and how key events can impact your business moving forward We go beyond simple “data collection” and reporting, combining market insight with leading-edge workshop facilitation expertise to drive robust decision making at all levels of your business.

Biosimilar Threats and Opportunities


The Issue Reflecting both sides of the challenge, our clients have required guidance to monitor and mitigate the threats to their biologics businesses, whilst also needing rapid decision making support to evaluate their potential entry into the biosimilars market.

The Issue

Our Approach Following secondary and primary research, our consultants managed a cross-functional client team at a major biotech to prioritize the most effective elements of its biosimilar defence strategy.

Our Approach Through in-depth secondary market research, detailed quantitative case study analysis, and primary interviews with internal and external experts, we were able to identify the key market factors determining whether PHC has a positive or negative impact upon a pharmaceutical product.

For a Japanese client considering investment in the biosimilars markets, we conducted rigorous secondary research and intensive evaluations across multiple workstreams to deliver robust understanding of local market drivers.

A large pharma client sought to understand how the introduction of personalized healthcare (PHC) affects the commercial performance of drugs launching into, or already on the market.

The Result Our biotech client benefited from a multiscenario impact model and decision support

The Result A PHC checklist of actions was developed along with an exhaustive report including ‘actions to

matrix that enabled them to plan for the impact of biosimilars on their business in nine individual markets. In Japan, our client adjusted their biosimilars entry strategy, based on our timely coverage and synthesis of local market insights.

imitate and to avoid’. The client used our report and quantitative model to inform their broader organization about the impact of PHC on drug sales across classes or disease areas.

Our consultants operate globally; our head offices are located in: UK 119 Farringdon Road, London EC1R 3DA | +44 (0)20 7675 7000 US 52 Vanderbilt Avenue, 7th Floor, New York, NY 10017 | +1 (212) 686 7400 Japan 7th Kotakudo GINZA Building, 5-14-5, Ginza, Chuo, Tokyo 104-0061 | +81 (0)3 5148 7910

Managing Market Disruptions in the Pharmaceutical and Biotechnology Industry